FDA approves Allecra’s EXBLIFEP for cUTI treatment

2024-02-28
Pharmaceutical Technology
临床3期引进/卖出上市批准临床结果
FDA approves Allecra’s EXBLIFEP for cUTI treatment
Preview
来源: Pharmaceutical Technology
EXBLIFEP treatment is indicated for usage in patients aged 18 years and above with complicated urinary tract infections. Credit: Albina Gavrilovic / Shutterstock.com.
EXBLIFEP is indicated for patients aged 18 years and above.
The approval is accompanied by a five-year marketing exclusivity extension from the US regulator under the Generating Antibiotic Incentives Now (GAIN) Act.
The GAIN Act offers incentives for developing new anti-infective drugs by granting benefits to qualified infectious disease product manufacturers.
The FDA granted the approval based on comprehensive clinical data highlighting the effectiveness of EXBLIFEP  against antimicrobial resistance in gram-negative bacteria, particularly resistance caused by extended spectrum beta lactamases and ampC enzymes.
See Also:MHRA streamlines approval process for established medicines
FDA approves Allecra’s EXBLIFEP for cUTI treatment
Preview
来源: Pharmaceutical Technology
Beyond approval: Patients pursue alternate paths to get rare disease treatments
FDA approves Allecra’s EXBLIFEP for cUTI treatment
Preview
来源: Pharmaceutical Technology
The data included results from the Phase III ALLIUM clinical trial in which EXBLIFEP demonstrated superiority to piperacillin/tazobactam in clinical cure and microbiological eradication in cUTI patients.
Allecra holds an extensive patent estate for the therapy in key markets, with the GAIN Act extending market exclusivity until 2032.
Orchid Pharma discovered enmetazobactam, a component of EXBLIFEP, and assigned all rights outside India to Allecra Therapeutics in 2013.
Since then, Allecra has been solely responsible for the global clinical and regulatory development of EXBLIFEP.
The company has completed exclusive licensing agreements with Shanghai Haini Pharmaceutical in Greater China and ADVANZ PHARMA in Europe.
In another global Phase III trial, EXBLIFEP was analysed against piperacillin / tazobactam, a standard cUTI care, showcasing its potential in a randomised, controlled, double-blind setting.
Allecra’s commercial partner, Advanz Pharma, sought marketing authorisation for EXBLIFEP in Europe.
Allecra Therapeutics supervisory board member Iain Buchanan said: “Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small yet highly focused team of individuals.
“As we continue our discussions with strategic partners for product launch in the US, we value the FDA’s positive decision on EXBLIFEP’s ability to address a critical unmet medical need for patients.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。